Product logins

Find logins to all Clarivate products below.


Chronic pain is a broad term encompassing many nociceptive, inflammatory, and neuropathic pain subtypes that can result from complex mechanisms affecting multiple pathophysiological pathways in the peripheral and central nervous systems; such complexity leads to difficulty for physicians in determining the mechanisms causing pain and, consequently, in finding an effective treatment for each patient. Primary care physicians and pain specialists use several drug classes, including antiepileptics, antidepressants, NSAIDs, and opioid analgesics, largely in an escalating sequence to provide adequate analgesia to patients, each of whom responds differently to available therapies based on individual pain etiologies. Opioid analgesics remain the class leader in treating chronic pain, although recent efforts in the United States to curb problems with overprescribing of opioid analgesics and to reduce the risk of abuse/misuse associated with these therapies have had a small but steadily growing impact on prescribing of this class for chronic pain patients with a history of, or at high risk of, abuse.

Related Market Assessment Reports

Report
Multiple Myeloma – Current Treatment – Treatment Sequencing – Multiple Myeloma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Report
Epilepsy – Unmet Need – Unmet Need – Dravet Syndrome (US/EU)
Dravet syndrome (DS) is a rare, severe, pediatric-onset genetic epileptic encephalopathy that typically emerges within the first year of life and is marked by developmental delays and multiple…
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
Report
Breast Cancer – Unmet Need – Unmet Need – Metastatic HR-Positive / HER2-Negative Breast Cancer (US/EU)
The landscape of advanced HR-positive / HER2-negative breast cancer treatment is continually evolving. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio)…
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…